CMAC Innovative Pharmaceutical Medicine Conference | Mr. Zhang Ronghuo, Vice President, has been Appointed as an Expert Member of the IRC Alliance of CMAC

The 2024 China (Suzhou) Innovative Pharmaceutical Medicine Conference and CMAC Annual Conference were grandly held from March 21st to 24th at the Suzhou International Expo Center. The theme of this conference is "Focusing on Medical Value and Building an Innovative Ecology Together", which has attracted numerous industry elites and experts and scholars to come for exchange and discussion. Mr. Zhang Ronghuo, Vice President of Leadingpharm and General Manager of Clinical Division, was invited to attend this grand event and appointed as an expert committee member of the first CMAC Center Imaging IRC Alliance.
 

As an authoritative institution in the pharmaceutical field, IRC plays a crucial role in clinical trials. Its independent, stable, and scientific imaging evaluation mechanism effectively reduces subjective bias and objective variability in evaluation, providing reliable data support for clinical research of innovative drugs, and has been widely applied in multiple fields such as medical aesthetics, oncology, and new imaging technologies.
 

Leadingpharm has accumulated rich experience in innovative drug clinical research. In the future, we will deepen cooperation with industry colleagues and jointly promote the standardization and normalization process of independent imaging evaluation.
 

During the conference, Dr. Zhu Haobin from Medical Department of Leadingpharm shared the challenges and opportunities encountered in the application of independent image assessment in the field of medical aesthetics clinical trials, based on Leadingpharm's rich experience in drugs and devices, and considering factors such as review risks, at the theme forum of IRC.
 

At the establishment ceremony of the CMAC Center Imaging IRC Alliance, five experts, including Mr. Zhang Ronghuo, Vice President of Leadingpharm, were appointed as expert members of Expert Committee Member of IRC.
 

Leadingpharm has always been committed to providing comprehensive clinical research services to global pharmaceutical innovation enterprises. With rich industry experience, a vast network of clinical trial institutions, and a strong professional team, Leadingpharm has provided over 500 research and development support and clinical technology services to more than 300 well-known enterprises worldwide, covering multiple fields such as biopharmaceuticals, chemical drugs, traditional Chinese medicine, cell and gene therapy. In cutting-edge fields such as medical aesthetics, specialty food, cell and gene therapy drugs, Leadingpharm has taken the lead in conducting clinical research and achieved significant results, filling multiple gaps at home and abroad.
 

Leadingpharm has always been committed to providing comprehensive clinical research services to global pharmaceutical innovation enterprises. With rich industry experience, a vast network of clinical trial institutions, and a strong professional team, Leadingpharm has provided over 500 research and development support and clinical technology services to more than 300 well-known enterprises worldwide, covering multiple fields such as biopharmaceuticals, chemical drugs, traditional Chinese medicine, cell and gene therapy. In cutting-edge fields such as medical aesthetics, specialty food, cell and gene therapy drugs, Leadingpharm has taken the lead in conducting clinical research and achieved significant results, filling multiple gaps at home and abroad.